Renin-angiotensin system and cardiovascular risk (Q36784673)

16 August 2017

title

Renin-angiotensin system and cardiovascular risk. (English)

1 reference

16 August 2017

1 reference

Roland E Schmieder

1 reference

16 August 2017

Karl F Hilgers

1 reference

16 August 2017

Markus P Schlaich

series ordinal

1 reference

16 August 2017

Bernhard M W Schmidt

series ordinal

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

369

1 reference

16 August 2017

issue

9568

1 reference

16 August 2017

page(s)

1208-1219

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

16 August 2017

1 reference

7 January 2021

Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Local renin-angiotensin systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-converting enzyme 2 protects from severe acute lung failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

The angiotensin IV/AT4 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin IV Activates the Nuclear Transcription Factor-κB and Related Proinflammatory Genes in Vascular Smooth Muscle Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Renin, prorenin and the putative (pro)renin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-converting enzyme 2 is an essential regulator of heart function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

The angiotensin II AT2 receptor is an AT1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Renin uptake by the endothelium mediates vascular angiotensin formation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Elevated blood pressure and heart rate in human renin receptor transgenic rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin blockade for hypertension: a promise fulfilled

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Losartan increases bradykinin levels in hypertensive humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Renin inhibition with aliskiren: where are we now, and where are we going?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

The role of non-haemodynamic factors of the genesis of LVH

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Relations between cardiac and vascular structure in patients with primary and secondary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Hyper-responsiveness to angiotensin II is related to cardiac structural adaptation in hypertensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Atrial fibrillation in hypertension: predictors and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Is atrial fibrillation an inflammatory disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

The antiarrhythmic potential of angiotensin II antagonism: experience with losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Inflammation in the genesis and perpetuation of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Histological Substrate of Atrial Biopsies in Patients With Lone Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Targeting brain AT1 receptors by RNA interference

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Strategies to achieve coronary arterial plaque stabilization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Attenuation of tissue P-selectin and MCP-1 expression and intimal proliferation by AT(1) receptor blockade in hyperlipidemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Increased NADH-Oxidase–Mediated Superoxide Production in the Early Stages of Atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Regulatory functions of the vascular endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Prognostic value of coronary vascular endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Circulating endothelial progenitor cells and cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Effect of AT1 receptor blockade on endothelial function in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularised syngeneic mouse islet grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Antihypertensive agents for primary prevention of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Efficacy and safety of benazepril for advanced chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

ACE-inhibitor use and the long-term risk of renal failure in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960242-6

7 January 2021

10.1016/S0140-6736(07)60242-6

Identifiers

DOI

1 reference

16 August 2017

1 reference